2022 World Conference on Lung Cancer (ePosters)-EP07.01-012. Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma

Pdf Summary

Researchers at the Clinic for Pulmonology at UMC Zagreb have found that combination immunotherapy with ipilimumab and nivolumab shows promise as a treatment option for patients with malignant pleural mesothelioma (MPM). The study involved 13 patients with non-resectable MPM who had previously progressed on regular chemotherapy regimens. The patients received ipilimumab (1mg/kg/6weeks) and nivolumab (3mg/kg/2weeks) treatment. The median age of the patients was 69.7 years, with one female and twelve male patients participating in the treatment. <br /><br />After a median treatment time of 15.9 weeks, data showed no deaths and a median progression-free survival (mPFS) of 20.3 weeks. Four patients experienced disease progression during this time. The study did not find a significant difference in progression-free survival between patients who started the treatment in the second line versus the third line. However, rapid disease progression on first-line therapy may indicate a poorer disease response to immunotherapy. The researchers note that more data is needed to confirm or refute these results.<br /><br />Overall, the combination immunotherapy with ipilimumab and nivolumab was well tolerated, with minimal side effects observed. One patient experienced grade 2 mucositis/gingivitis, which required only a 7-day treatment delay and symptomatic therapy. Another patient had grade 1-2 hyperthyroidism, which did not require any treatment delay. No grade 3 or higher side effects were observed in any of the patients.<br /><br />The researchers conclude that ipilimumab and nivolumab combination immunotherapy appears to be a viable treatment option for pretreated patients with malignant pleural mesothelioma. The initial results are promising, and the researchers hope that more data will continue to show a positive response to the treatment.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

Keywords

Clinic for Pulmonology

UMC Zagreb

combination immunotherapy

ipilimumab

nivolumab

malignant pleural mesothelioma

non-resectable MPM

chemotherapy regimens

progression-free survival

side effects